Aptamer engineering of lentiviral vectors for cardiac gene therapies
Ended Project Grant Awarded Last action
- Award ID
- R43HL170830
- Recipient
-
Base Pair Biotechnologies Inc. UEI FFAKKLCKBNN7
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $289,665
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Place of performance
- Texas, USA
Award details come from USAspending.gov.
Description
- Abstract
- Overview: hypertrophic cardiomyopathy is the leading cause of sudden death in young individuals, where several loss-of-function mutations in key sarcomeric proteins cause hypertrophy. Gene therapy approaches that drive the overexpression of the correct genes can be used to remodel the heart tissue and restore function. However, no gene therapies have been developed for in vivo targeting of the heart to date. A key bottleneck in the field is the ability to engineer advanced viral vectors with prescribed tropism in the patient's body. Lentiviral vector (LVV) engineering applies rational design principles to define components of the vector envelope, such as attachment proteins, leading to vectors with programmable tissue specificity and off-target activity.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $289,665 |
Quick answers
Who received award R43HL170830?
R43HL170830 was awarded to Base Pair Biotechnologies Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 11, 2023.
How much is award R43HL170830 worth?
$289,665 has been obligated on R43HL170830.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award